Heart Failure Induced by Non-Cardiac Drugs

Abstract

Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely affect haemodynamic mechanisms in patients with an already existing heart condition. In this article, non-cardiac drugs known to be associated with the development or worsening of heart failure are reviewed. Moreover, drugs that may adversely affect the heart as a pump without causing symptoms or signs of heart failure are also included. The drugs discussed include anticancer agents such as anthracyclines, mitoxantrone, cyclophosphamide, fluorouracil, capecitabine and trastuzumab; immunomodulating drugs such as interferon-alpha-2, interleukin-2, infliximab and etanercept; antidiabetic drugs such as rosiglitazone, pioglitazone and troglitazone; antimigraine drugs such as ergotamine and methysergide; appetite suppressants such as fenfulramine, dexfenfluramine and phentermine; tricyclic antidepressants; antipsychotic drugs such as clozapine; antiparkinsonian drugs such as pergolide and cabergoline; glucocorticoids; and antifungal drugs such as itraconazole and amphotericin B. NSAIDs, including selective cyclo-oxygenase (COX)-2 inhibitors, are included as a result of their ability to cause heart disease, particularly in patients with an already existing cardiorenal dysfunction. Two drug groups are of particular concern. Anthracyclines and their derivatives may cause cardiomyopathy in a disturbingly high number of exposed individuals, who may develop symptoms of insidious onset several years after drug therapy. The risk seems to encompass all exposed individuals, but data suggest that children are particularly vulnerable. Thus, a high degree of awareness towards this particular problem is warranted in cancer survivors subjected to anthracycline-based chemotherapy. A second group of problematic drugs are the NSAIDs, including the selective COX-2 inhibitors. These drugs may cause renal dysfunction and elevated blood pressure, which in turn may precipitate heart failure in vulnerable individuals. Although NSAID-related cardiotoxicity is relatively rare and most commonly seen in elderly individuals with concomitant disease, the widespread long-term use of these drugs in risk groups is potentially hazardous. Pending comprehensive safety analyses, the use of NSAIDs in high-risk patients should be discouraged. In addition, there is an urgent need to resolve the safety issues related to the use of COX-2 inhibitors. As numerous drugs from various drug classes may precipitate or worsen heart failure, a detailed history of drug exposure in patients with signs or symptoms of heart failure is mandatory.

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

“…Also, concomitant medications (e.g., vasodilators, nonsteroidal anti-inflammatory drugs, glucocorticoids, and herbal drugs containing licorice) that may contribute to fluid retention should be identified. [85][86][87] All patients should be monitored for new pedal edema, weight gain of more than 3 kg, dyspnea, or fatigue. 85 Appropriate patient selection, titration, patient education, and monitoring can help minimize ADEs associated with the use of TZDs.…”

Doxorubicin-induced chronic dilated cardiomyopathy—the apoptosis hypothesis revisited

“…However, DOX clinical utility and dosage regimens are often limited by severe side effects which can be either acute, sub-acute or late and chronic [5]. While acute and sub-acute toxicity are rare (1-4%) and can be managed by adaptation of dosage regimens during, or cessation of, treatment, chronic side effects occur often several years after treatment [6].…”

Cyclophosphamide-induced Cardiotoxicity with a Prolonged Clinical Course Diagnosed on an Endomyocardial Biopsy

“…Acute symptoms usually occur within three weeks, last for a few weeks and, in some patients, resolve without late consequences (1,2,8). However, approximately 11% of those who receive high-dose CY develop fatal cardiomyopathy (12). In the present case, symptoms of heart failure gradually appeared approximately two months after the administration of CY, and the patient took approximately one year to recover with conventional pharmacotherapy for heart failure, including angiotensin-receptor blockers and betablockers.…”